Allergy Therapeutics PLC (LON:AGY) said it has completed the treatment of all patients taking part in an exploratory field study of its short-course inoculation against grass pollen-induced hay fever.
Assessing the safety and efficacy of the new injection, results from this assessment, due in the second half of this year, will feed into the design of Allergy’s phase III trial of Grass MATA MPL.
Chief executive Manuel Llobet said: “This ground-breaking exploratory trial design has the potential to greatly increase our understanding of allergic rhinitis and how to effectively generate data for product registration via field trials.
“Challenges brought about by COVID-19 were alleviated by the excellent clinical team here at Allergy Therapeutics and we are very much looking forward to the results later this year.”
The phase III trial of the company’s new drug is set to get underway in the second half of next year.
The latest field study was concluded with a 97% patient retention rate, which was remarkable given the challenges posed by COVID.